Skip to content
HowShorted

Accelerate Diagnostics, Inc short interest in 2022

In 2022, Accelerate Diagnostics, Inc's disclosed short interest ran from 10.00% of shares outstanding on 14 Jan 2022 to 4.53% on 30 Dec 2022, a change of -5.47 percentage points. The year's high was 10.89% on 15 Feb 2022 and its low 3.95% on 15 Nov 2022, averaging 7.89% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.42 days on 15 Feb 2022. Full history: Accelerate Diagnostics, Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Accelerate Diagnostics, Inc in 2022

2022 in figures

Start of year
10.00% (14 Jan 2022)
End of year
4.53% (30 Dec 2022)
Change
-5.47 pp
High
10.89% (15 Feb 2022)
Low
3.95% (15 Nov 2022)
Average
7.89%
Highest days to cover
27.42 (15 Feb 2022)
SEC filings marked
9

Every report in 2022

Accelerate Diagnostics, Inc short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202210.00%22.98results (8-K)
31 Jan 202210.67%19.71
15 Feb 202210.89%27.42
28 Feb 202210.47%26.09
15 Mar 202210.28%19.46results (8-K), 10-K filed
31 Mar 202210.42%16.68
14 Apr 202210.41%12.52
29 Apr 20229.89%8.73
13 May 20229.92%11.80
31 May 202210.28%6.9210-Q filed, results (8-K)
15 Jun 20229.92%2.79
30 Jun 20227.20%2.93
15 Jul 20227.59%14.01
29 Jul 20227.98%20.32
15 Aug 20226.93%8.6910-Q filed, results (8-K)
31 Aug 20226.32%1.68
15 Sep 20226.20%6.77
30 Sep 20226.02%18.91
14 Oct 20225.91%23.12
31 Oct 20224.87%7.94
15 Nov 20223.95%21.9410-Q filed, results (8-K)
30 Nov 20224.38%14.07
15 Dec 20224.37%13.88
30 Dec 20224.53%9.82

See also: Accelerate Diagnostics, Inc's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.